Relay Therapeutics Inc. reports fourth-quarter earnings Thursday, with analysts expecting a narrower loss as the clinical-stage biotech rides momentum from a major regulatory win. Analysts expect the ...
In Phase II data released this week, people taking a monthly dose of PF’3944 continued to lose more weight than those on a placebo. Reading time 2 minutes The competition to develop the next ...
Biomed Industries, Inc. Announces Two NA-931 Phase 3 Trials, Targeting Durable Weight Loss & Lean-Mass Preservation at JP Morgan Week 2026 Advancing NA-931, the first oral quadruple receptor ...
A Roche obesity drug designed to hit two targets led to weight loss that is competitive with other drugs in its class, but from a development standpoint, the drug candidate still trails rival ...
Roche obesity drug shows 22.5% weight loss in Phase-II trial Roche focuses on catching Lilly in $150 billion obesity market Investors lukewarm on CT-388 results in crowded market The company said on ...
(RTTNews) - Genentech, a biotechnology firm and member of the Roche Group (RHHBY,ROG.SW), announced positive topline results from its Phase 2 clinical trial of CT-388 in obesity. CT-388 is an ...
A new technical paper titled “Hybrid tungsten oxyselenide/graphene electrodes for near-lossless 2D semiconductor phase modulators” was published by researchers at Nanyang Technological University, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results